When the study patients were classified according to the WHO grade, CER1 and FSTL1 showed significantly higher expression, while FRAT1 showed significantly lower expression in patients with grade III glioma than in patients with grade II glioma (Supplementary Figure S3). Here, FSTL1 is linked to central nervous system cancer.